HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.

Abstract
In a canine copper coil-induced coronary thrombosis model, the differences in frequency of reperfusion arrhythmias (premature ventricular complexes: PVC) and mortality rate after thrombolysis by intravenous bolus injection of a novel modified tissue-type plasminogen activator (t-PA), E6010, and by continuous intravenous infusion of native t-PA or urokinase were evaluated. Rapid coronary occlusion and reperfusion were produced with a balloon catheter in another group of dogs, and the findings were compared with those in the thrombolysis groups. Reperfusion occurred gradually after the administration of E6010, but was significantly more rapid after administration of native t-PA and urokinase (P < 0.05). PVC were observed more frequently in native t-PA, urokinase and balloon occlusion-reperfusion groups than in the E6010 group. The mortality rate due to ventricular fibrillation was 0.0% in the E6010 group, 50.0% in the native t-PA and balloon occlusion-reperfusion groups, and 33.3% in the urokinase group. These results suggest that the more gradual reperfusion of the coronary artery at an earlier period after drug administration led to the lower frequency of reperfusion arrhythmias and low mortality rate in the E6010 group than in the native t-PA, urokinase and balloon occlusion-reperfusion groups.
AuthorsM Saito, S Suzuki, Y Yui, C Kawai
JournalJapanese journal of pharmacology (Jpn J Pharmacol) Vol. 66 Issue 1 Pg. 17-23 (Sep 1994) ISSN: 0021-5198 [Print] Japan
PMID7532243 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Fibrinolytic Agents
  • E 6010
  • Epidermal Growth Factor
  • Tissue Plasminogen Activator
  • Urokinase-Type Plasminogen Activator
Topics
  • Animals
  • Cardiac Complexes, Premature (physiopathology)
  • Catheterization
  • Coronary Circulation (drug effects)
  • Coronary Thrombosis (physiopathology)
  • Dogs
  • Epidermal Growth Factor (pharmacology)
  • Female
  • Fibrinolytic Agents (pharmacology)
  • Male
  • Myocardial Reperfusion Injury (physiopathology)
  • Tissue Plasminogen Activator (pharmacology)
  • Urokinase-Type Plasminogen Activator (pharmacology)
  • Ventricular Fibrillation (physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: